Document:

exv10w2

 

Exhibit 10.2

CONSULTING AGREEMENT

          This Consulting Agreement (this “Agreement”) is entered into by and between L. Clark Wood
(“Consultant”) and The Greenbrier Companies, Inc. (“Greenbrier”) effective as of May 1, 2007.
Consultant is retiring from the position of President, Greenbrier Manufacturing Operations as of
April 30, 2007 and the parties desire to enter into this Agreement in order to provide for an
orderly transition of functions and duties in connection with Consultant’s retirement. The parties
hereby agree as follows:

     1. Consulting Term. The “Consulting Term” will commence on May 1, 2007 and will extend for a
period of one year thereafter, subject to the following sentence. On May 1, 2008 and on each
successive anniversary of that date (the “Anniversary Date”), the Consulting Term will be
automatically extended and renewed for one additional year unless, not less than 30 days prior to
such Anniversary Date, Consultant or Greenbrier gives written notice to the other that the
Consulting Term will not be so extended and renewed.

     2. Consulting Services. During the Consulting Term, Consultant will provide consulting
services to Greenbrier to support Greenbrier Manufacturing Operations (the “Consulting Services”),
as directed by the President of Greenbrier (the “President”). Consultant will providing Consulting
Services to Greenbrier averaging up to forty hours (one week) per month, unless a different number
of hours is mutually agreed to by Consultant and the President at any given time. Consultant is a
Texas resident and may work from his home in Texas; however, the parties anticipate that Consultant
travel to Greenbrier’s corporate headquarters as necessary.

     3. Consulting Fees. For up to 40 hours per month of work undertaken pursuant to this
Agreement, Greenbrier will pay Consultant a fee in the amount of $7,500.00 per month (the
“Consulting Fee”). In the event that Consultant works in excess of 40 hours per month at the
request of the President during any period or periods, Greenbrier will pay Consultant an additional
Consulting Fee for such periods in an amount to be mutually agreed upon by Consultant and the
President.

     4. Insurance; Expenses; Use of Company Property. During the Consulting Term Greenbrier will
continue to cover Consultant and his spouse under Greenbrier’s group health plan, and will pay the
cost of the premiums for such coverage. Consultant will not be eligible to participate in or
receive benefits under any other employee benefit or executive compensation plans or programs
sponsored or maintained by Greenbrier or any of its subsidiaries. The foregoing sentence is not
intended to effect any rights that Consultant may have to receive payment of any benefits that
accrued to him while he was an employee of Greenbrier or any of its subsidiaries. Greenbrier will
reimburse Consultant for all reasonable and ordinary business expenses incurred in the performance
of Consulting Services under this Agreement, provided that Consultant properly accounts for such
expenses in the manner prescribed by Greenbrier from time to time. Consultant will have the use of
a company-owned vehicle, lap-top computer and cell phone during the Consulting Term.

     5. Independent Contractor Status. Consultant’s status will be that of an independent
contractor, and nothing contained in this Agreement is intended to operate or be

Consulting Agreement

Page 1

 

 

construed to create an employment relationship between the parties. Consultant will be solely
responsible for determining the means and methods by which the Consulting Services are performed
under this Agreement. Payment of all income, FICA and any other applicable taxes arising from
Consultant’s performance under this Agreement will be the responsibility of Consultant.

     6. Noncompetition and Nonsolicitation. During the Consulting Period and for a period of two
(2) years thereafter Consultant will not directly or indirectly:

          (a) own (as an asset or equity owner), or be employed by or consult for, any business,
including, without limitation, L. Clark Wood Consulting, Inc. in direct competition with the
Company in the same or substantially related product or service lines in which the Company is
engaged, or in which the Company reasonably expects to engage during the two-year restriction
period; provided that ownership of one percent (1%) or less of the outstanding stock of a publicly
traded corporation will not be deemed to be a violation of this Agreement. The term “Company”
includes Greenbrier and its subsidiaries, subdivisions, branches and affiliates.

          (b) either (i) solicit for himself or for a directly competing company or business
organization, any person or entity that is a customer, vendor or supplier or prospective customer,
vendor or supplier of the Company or was a customer, vendor or supplier or a prospective customer,
vendor or supplier of the Company prior to or during the Consulting Term, or (ii) solicit for
himself or any such directly competing company or business organization, any employee of the
Company, whether or not such employee’s employment is pursuant to a written agreement and whether
or not such employment is for a determined period or is at will. For the purposes of this
Agreement, a customer of the Company means any entity or person which purchases, leases or licenses
goods or services from the Company.

          (c) Consultant acknowledges and agrees that a breach of any provision of this Section 6 will
cause irreparable damage to Greenbrier and that in the event of such breach Greenbrier will have,
in addition to any and all remedies of law, the right to an injunction, specific performance or
other equitable relief to prevent the violation of my obligations under this Agreement. Any waiver
by Greenbrier of a breach of any provision of this Agreement will not operate or be construed as a
waiver of any subsequent breach of such provision or any other provision of this Agreement.

     7. Modification or Termination. This Agreement may be amended, modified or terminated only by
mutual agreement of Consultant and Greenbrier. Any amendment or modification of this Agreement
will be valid only if in a writing signed by both parties.

     8. Severability. Each provision in this Agreement will be treated as a separate and
independent clause, and the unenforceability of any one clause will in no way impair the
enforceability of any of the other clauses in this Agreement. Moreover, if one or more of the
provisions contained in this Agreement for any reason is held to be excessively broad as to scope,
activity or subject so as to be unenforceable at law, such provision or provisions will be
construed by the appropriate arbitral or judicial body by limiting and reducing it or them, so as
to be enforceable to the maximum extent compatible with the applicable law as it then exists.

Consulting Agreement

Page 2

 

 

     9. Binding Effect; Assignment. This Agreement will be binding upon and inure to the benefit
of both parties and their respective successors, assigns, heirs and personal representatives. The
obligations of the Consultant under this Agreement are personal and may not be assigned by
Consultant.

     10. Governing Law; Dispute Resolution. This Agreement will be governed by, and construed in
accordance with, the laws of the State of Oregon without regard to choice of law rules. Any
controversy or claim arising out of or relating to this Agreement will be settled by final and
binding arbitration in Portland, Oregon, by a single, neutral arbitrator administered by the
Arbitration Service of Portland, Inc. Any filing fee charged by the arbitrator initially and all
arbitrator fees and hearing session fees that are required to be paid in advance will be paid by
Greenbrier, pending a determination by the arbitrator of the prevailing party. Consultant is a
resident of the state of Texas. Greenbrier is headquartered in the state of Oregon. Consultant
specifically agrees that the venue of any arbitration proceeding will be Portland, Oregon and
specifically irrevocably consents and submits to the jurisdiction of any Oregon court with
jurisdiction over the subject matter to compel arbitration under this Agreement or to enforce an
arbitration award, and hereby waives any objection to jurisdiction and venue in any such court, and
waive any claim that such forum is an inconvenient forum. Notwithstanding the provisions of this
Section 10, nothing herein will prevent either party from bringing a claim in a court of competent
jurisdiction to compel arbitration under this Agreement or to enforce an arbitration award.
Consultant specifically waives any right he may have to commence an action in state or federal
court in Texas with respect to any controversy or claim arising out of or relating to this
Agreement.

          IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the date first
written above.

	 	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	COMPANY:	 	 	 	CONSULTANT:	 	 
	 
	 	 	 	 	 	 	 	 
	The Greenbrier Companies, Inc.	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ William A. Furman
	 	 	 	/s/ L. Clark Wood	 	 
	 

	 	 
	 	 	 	 	 	 
	Title: President and CEO	 	 	 	L. Clark Wood	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	L. Clark Wood Consulting, Inc. agrees to be
bound by the provisions of paragraphs 6 and
10 of this agreement.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	L. Clark Wood Consulting, Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	/s/ L. Clark Wood	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	By	 	 

Consulting Agreement

Page 3exv10w1

 

Exhibit 10.1

COMMON STOCK PURCHASE AGREEMENT

     This Common Stock Purchase Agreement (the “Agreement”) is made and entered into
as of July 10, 2007 (the “Effective Date”) by and between Sangamo BioSciences, Inc., a
Delaware corporation having its principal place of business at Point Richmond Tech Center, 501
Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and Sigma-Aldrich
Corporation, a Delaware corporation having its principal place of business at 3050 Spruce
Street, St. Louis, MO 63103 (“Sigma”). Sangamo and Sigma are sometimes referred to herein
individually as a “Party” and collectively as the “Parties.”

     Whereas, Sigma and Sangamo are party to that certain License Agreement of even date
herewith (the “License Agreement”);

     Whereas, pursuant to Section 7.1 of the License Agreement, Sangamo desires to issue,
and Sigma desires to acquire, such number of shares of common stock of Sangamo as herein described,
on the terms and conditions hereinafter set forth.

     Now, Therefore, It Is Agreed between the Parties as follows:

ARTICLE 1

Definitions

     1.1 “Basic Prospectus” means the basic prospectus included in the Registration Statement.

     1.2 “Closing” has the meaning set forth in Section 2.2.

     1.3 “Business Day” means any day except Saturday, Sunday, any day which shall be a federal
legal holiday in the United States or any day on which banking institutions in the State of New
York are authorized or required by law or other governmental action to close.

     1.4 “Common Stock” means the common stock, par value $0.01 per share, of Sangamo.

     1.5 “Exchange Act” means the Securities Exchange Act of 1934, as amended.

     1.6 “Governmental Authority” means any United States, state, local or foreign governmental
entity or municipality or subdivision thereof or any authority, department, commission, board,
bureau, agency, court or instrumentality.

     1.7 “Knowledge of Sangamo” means the actual knowledge of the individuals listed on Schedule
1.7.

     1.8 “Prospectus” means the Prospectus Supplement together with the Basic Prospectus.

 

 

     1.9 “Prospectus Supplement” means the supplement to the Basic Prospectus complying with Rule
424(b) of the Securities Act that is filed with the Commission and delivered by Sangamo to Sigma in
connection with the Closing.

     1.10 “Registration Statement” means the registration statement on Form S-3 (File No.
333-142425), as amended at the time of such registration statement’s effectiveness for purposes of
Section 11 of the Securities Act, including all documents filed as a part thereof or incorporated
or deemed to be incorporated by reference therein.

     1.11 “SEC” or “Commission” means the United States Securities and Exchange Commission.

     1.12 “Securities Act” means the Securities Act of 1933, as amended.

     1.13 “Shares” has the meaning set forth in Section 2.1.

     1.14 “Subsidiary” has the meaning set forth in Section 3.7.

ARTICLE 2

Purchase and Sale of Stock

     2.1 Purchase and Sale. At the Closing, Sangamo hereby agrees to sell and Sigma hereby agrees
to purchase 1,000,000 shares of Common Stock (the “Shares”) at a purchase price of $7.75 per share,
which represents the average of the closing prices for Sangamo’s Common Stock for the 30 trading
days immediately prior to the date hereof.

     2.2 Closing. Payment of the purchase price for, and delivery of, the Shares shall be made at
a closing (the “Closing”) at the offices of Morgan, Lewis & Bockius LLP, securities counsel for
Sangamo, located at One Market Street, San Francisco, California at 7:00 a.m., local time, on July
13, 2007, or at such other time and date determined by mutual agreement between Sangamo and Sigma,
provided that the Closing shall occur no later than the third Business Day after the date hereof.
All such actions taken at the Closing shall be deemed to have occurred simultaneously. At the
Closing, Sangamo shall deliver to Sigma a certificate representing the Shares being purchased by
Sigma pursuant to this Agreement against payment of the purchase price therefor by wire transfer to
a bank account designated by Sangamo.

ARTICLE 3

Representations , Warranties and Covenants of Sangamo 

     Sangamo represents and warrants to, and covenants and agrees with, Sigma as of the date hereof
and as of the date of Closing, as follows:

     3.1 Filing and Effectiveness of Registration Statement. Sangamo has prepared and filed, in
conformity with the requirements of the Securities Act of 1933, as amended (the

 2.

 

“Securities Act”), and the published rules and regulations thereunder (the “Rules and
Regulations”) adopted by the Commission, a registration statement on Form S-3 (No. 333-142425),
relating to the Shares and the offering thereof from time to time in accordance with Rule 415 of
the Rules and Regulations, and such amendments thereof as may have been required to date. The
Registration Statement has heretofore become effective under the Securities Act. No stop order
preventing or suspending the effectiveness of the Registration Statement has been issued by the
Commission, and no proceedings for such purpose pursuant to Section 8A of the Securities Act
against Sangamo have been instituted or are pending or, to Sangamo’s knowledge, are contemplated or
threatened by the Commission, and any request received by the Company on the part of the Commission
for additional information has been complied with. Sangamo meets the requirements for use of Form
S-3 under the Securities Act and has complied with the requirements of Rule 415 with respect to the
Registration Statement.

     3.2 Compliance with Securities Act Requirements. The Registration Statement complied when it
became effective, complies as of the date hereof and, as amended or supplemented, and at all times
during which a prospectus is required by the Securities Act to be delivered (whether physically or
through compliance with Rule 172 under the Securities Act or any similar rule) in connection with
any sale of Shares, will comply, in all material respects, with the requirements of the Securities
Act and the Rules and Regulations; the Registration Statement, when it became effective, did not
contain an untrue statement of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, provided, that Sangamo
makes no representations or warranty in this paragraph with respect to statements in or omissions
from the Registration Statement in reliance upon, and in conformity with, written information
furnished to Sangamo by Sigma or its counsel specifically for inclusion therein.

     3.3 Contents of Prospectus. The Prospectus complied, as of the date that it is filed with the
Commission, and complies as of the date hereof, in all material respects, with the requirements of
the Securities Act (in the case of the Prospectus, including, without limitation, Section 10(a) of
the Securities Act); the Prospectus, on the date of such Prospectus and at Closing, did not and
will not include an untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading, provided, that Sangamo makes no representations or warranty in this
paragraph with respect to statements in or omissions from the Prospectus in reliance upon, and in
conformity with, written information furnished to Sangamo by Sigma or its counsel specifically for
inclusion therein.

     3.4 Incorporated Documents. Each of the documents incorporated or deemed to be incorporated
by reference in the Registration Statement, at the time such document was filed with the Commission
or at the time such document became effective, as applicable, complied, in all material respects,
with the requirements of the Exchange Act and did not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading.

     3.5 Not an Ineligible Issuer. (1) At the time of the filing of the Registration Statement and
(2) at Closing, Sangamo was not and is not an “ineligible issuer,” as defined in

 3.

 

Rule 405 (“Rule 405”) under the Securities Act.

     3.6 Due Incorporation. Sangamo has been duly organized and is validly existing as a
corporation in good standing under the laws of the State of Delaware, with the corporate power and
authority to own its properties and to conduct its business as currently being conducted and as
described in the Registration Statement and the Prospectus and is duly qualified to transact
business and is in good standing as a foreign corporation in each other jurisdiction in which its
ownership or leasing of property or the conduct of its business requires such qualification, except
where the failure to be so qualified and in good standing or have such power or authority (i) would
not have, individually or in the aggregate, a material adverse effect upon, the general affairs,
business, operations, prospects, properties, financial condition, or results of operations of
Sangamo and its Subsidiaries (as defined below), taken as a whole, or (ii) impair in any material
respect the power or ability of Sangamo to perform its obligations under this Agreement or to
consummate any transactions contemplated by this Agreement (any such effect as described in clauses
(i) or (ii), a “Material Adverse Effect”).

     3.7 Subsidiaries. Sangamo has no significant subsidiaries (as such term is defined in Rule
1-02 of Regulation S-X promulgated by the Commission) other than as set forth on Schedule
3.7 hereto (each, a “Subsidiary” and collectively, the “Subsidiaries”). Each Subsidiary has
been duly organized and is validly existing as a corporation or other legal entity in good standing
(or the foreign equivalent thereof) under the laws of its jurisdiction of organization, with the
corporate power and authority to own its properties and to conduct its business as currently being
conducted and as described in the Registration Statement and the Prospectus. All of the issued and
outstanding capital stock (or similar equity interests) of each Subsidiary has been duly authorized
and validly issued and is fully paid and nonasssessable and, except as described in the
Registration Statement and Prospectus, are owned by Sangamo, directly or through subsidiaries, free
from liens, encumbrances and defects.

     3.8 Due Authorization and Enforceability. Sangamo has the full right, power and authority
to enter into this Agreement and to perform and discharge its obligations hereunder; this Agreement
has been duly authorized, executed and delivered by Sangamo, and constitutes a valid, legal and
binding obligation of Sangamo, enforceable against Sangamo in accordance with its terms, except as
rights to indemnity hereunder may be limited by federal or state securities laws and except as such
enforceability may be limited by applicable bankruptcy, insolvency, reorganization or similar laws
affecting the rights of creditors generally and subject to general principles of equity.

     3.9 The Shares. The issuance of the Shares has been duly and validly authorized by Sangamo
and, when issued, delivered and paid for in accordance with the terms of this Agreement, will have
been duly and validly issued and will be fully paid and nonassessable. Except as otherwise stated
in the Registration Statement and the Prospectus, there are no statutory or contractual preemptive
rights or other rights to subscribe for or purchase or acquire any shares of Common Stock of
Sangamo, which have not been waived or complied with and will conform in all material respects to
the description thereof contained in the Registration Statement and the Prospectus.

     3.10 Capitalization. The information set forth under the caption “Capitalization” in

 4.

 

the Prospectus (and any similar sections or information, if any, contained in the Registration
Statement) is fairly presented on a basis consistent with Sangamo’s financial statements. The
authorized capital stock of Sangamo conforms as to legal matters to the description thereof
contained in the Prospectus under the caption “Description of Common Stock” (and any similar
sections or information, if any, contained in the Registration Statement). The issued and
outstanding shares of capital stock of Sangamo have been duly authorized and validly issued, are
fully paid and nonassessable, and have been issued in compliance with all federal and state
securities laws. None of the outstanding shares of Common Stock was issued in violation of any
preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase or
acquire any securities of Sangamo. There are no authorized or outstanding shares of capital stock,
options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or
equity or debt securities convertible into or exchangeable for, any capital stock of Sangamo or any
of its Subsidiaries other than those described in the Prospectus and the Registration Statement.
The description of Sangamo’s stock option, stock bonus and other stock plans or arrangements, and
the options or other rights granted thereunder, as described in the Registration Statement and the
Prospectus, accurately and fairly present the information required to be shown with respect to such
plans, arrangements, options and rights.

     3.11 No Conflict. The execution, delivery and performance by Sangamo of this Agreement and
the consummation of the transactions contemplated hereby will not conflict with or result in a
breach or violation of, or constitute a default under (nor constitute any event which with notice,
lapse of time or both would result in any breach or violation of or constitute a default under),
give rise to any right of termination or other right or the cancellation or acceleration of any
right or obligation or loss of a benefit under, or give rise to the creation or imposition of any
lien, encumbrance, security interest, claim or charge upon any property or assets of Sangamo or any
Subsidiary pursuant to (i) any indenture, mortgage, deed of trust, loan agreement or other
agreement or instrument to which Sangamo or any Subsidiary is a party or by which any of them or
any of their respective properties may be bound or to which any of the property or assets of
Sangamo or any of its Subsidiaries is subject, (ii) result in any violation of the provisions of
the charter or by-laws of Sangamo or any Subsidiary, or (iii) result in any violation of any law,
statute, rule, regulation, judgment, order or decree of any court or governmental agency or body,
domestic or foreign, having jurisdiction over Sangamo or its Subsidiaries or any of their
properties or assets except, in the case of each of clauses (i) and (iii) above, for any such
conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or
in the aggregate, reasonably be expected to have a Material Adverse Effect.

     3.12 No Consents Required. No approval, authorization, consent or order of or filing,
qualification or registration with, any court or governmental agency or body, foreign or domestic,
which has not been made, obtained or taken and is not in full force and effect, is required in
connection with the issuance and sale of the Shares under this Agreement other than (i) as may be
required under the Securities Act or the Exchange Act, (ii) any necessary qualification of the
Shares under the securities or blue sky laws of the various jurisdictions, or (iii) as may be
required by Nasdaq Global Market in connection with the listing of the Shares.

     3.13 Registration Rights. Except as otherwise described in the Registration Statement and the
Prospectus, there are no contracts, agreements or understandings between Sangamo and any person
granting such person the right (other than rights which have been

 5.

 

waived in writing in connection with the transactions contemplated by this Agreement or
otherwise satisfied) to require Sangamo to register any securities with the Commission.

     3.14 Accountant. Ernst & Young LLP, whose reports on the audited consolidated financial
statements of Sangamo and the Subsidiaries are incorporated by reference in the Registration
Statement and the Prospectus are independent public accountants with respect to Sangamo as required
by the Securities Act, and the applicable published rules and regulations thereunder.

     3.15 Financial Statements. The consolidated financial statements of Sangamo, together with
the related schedules and notes thereto, set forth or incorporated by reference in the Registration
Statement and the Prospectus, comply in all material respects with the applicable requirements of
the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects
(i) the financial condition of Sangamo and the Subsidiaries, taken as a whole, as of the dates
indicated and (ii) the consolidated results of operations, stockholders’ equity and changes in cash
flows of Sangamo and the Subsidiaries, taken as a whole, for the periods therein specified; and
such financial statements and related schedules and notes thereto have been prepared in conformity
with United States generally accepted accounting principles, consistently applied throughout the
periods involved (except as otherwise stated therein and subject, in the case of unaudited
financial statements, to the absence of footnotes and normal year-end adjustments). There are no
other financial statements (historical or pro forma) that are required to be included or
incorporated by reference in the Registration Statement or the Prospectus.

     3.16 Absence of Material Changes. Subsequent to the respective dates as of which information
is given in the Registration Statement and the Prospectus, and except as may be otherwise stated or
incorporated by reference in the Registration Statement and the Prospectus, there has not been (i)
any change in the capital stock of Sangamo (except for changes in the number of outstanding shares
of Common Stock of Sangamo due to the issuance of shares upon the exercise or conversion of
securities exercisable for, or convertible into, shares of Common Stock outstanding on the date
hereof) or long-term debt of Sangamo or any of its Subsidiaries or any dividend or distribution of
any kind declared, set aside for payment, paid or made by Sangamo on any class of capital stock;
(ii) any material adverse change, or, to the knowledge of Sangamo, any development that would
result in a material adverse change in or affecting the general affairs, business, prospects,
properties, management, consolidated financial position, stockholders’ equity or results of
operations of Sangamo and its Subsidiaries taken as a whole; (iii) neither Sangamo nor any of its
Subsidiaries have entered or will enter into any transaction or agreement, not in the ordinary
course of business, that is material to Sangamo and its Subsidiaries taken as a whole or incurred
or will incur any liability or obligation, direct or contingent, not in the ordinary course of
business, that is material to Sangamo and its Subsidiaries taken as a whole; and (iv) neither
Sangamo nor any of its Subsidiaries has sustained or will sustain any material loss or interference
with its business from any force majeure, including fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor disturbance or dispute or any action, order
or decree of any court or arbitrator or governmental or regulatory authority, except in each case
as otherwise disclosed in the Registration Statement and the Prospectus.

     3.17 Legal Proceedings. There are no legal or governmental actions, suits, claims or

 6.

 

proceedings pending (including, without limitation, any proceedings pending before the Food
and Drug Administration of the U.S. Department of Health and Human Services (the “FDA”)) to which
Sangamo or any Subsidiary is or would be a party or of which any of their respective properties is
or would be subject at law or in equity, which are required to be described in the Registration
Statement or the Prospectus or a document incorporated by reference therein and are not so
described therein, or which, singularly or in the aggregate, if resolved adversely to Sangamo or
any Subsidiary, would reasonably be likely to result in a Material Adverse Effect or prevent or
materially and adversely affect the ability of Sangamo to consummate the transactions contemplated
hereby. To Sangamo’s knowledge, no such proceedings are threatened or contemplated by governmental
authorities or threatened by others.

     3.18 Permits. Sangamo and each Subsidiary has made all filings, applications and submissions
required by, and owns or possesses all approvals, licenses, certificates, certifications,
clearances, consents, exemptions, marks, notifications, orders, permits and other authorizations
issued by, the appropriate federal, state or foreign regulatory authorities (including, without
limitation, the FDA, and any other foreign, federal state or local government or regulatory
authorities performing functions similar to those performed by the FDA) necessary to conduct its
business as described in the Registration Statement and the Prospectus (collectively, “Permits”),
except for such Permits which the failure to obtain would not have a Material Adverse Effect (the
“Immaterial Permits”), and is in compliance in all material respects with the terms and conditions
of all such Permits other than the Immaterial Permits (the “Required Permits”). Neither Sangamo
nor any Subsidiary has received notice of any proceedings relating to revocation or modification
of, any such Required Permit, which, individually or in the aggregate, if the subject of an
unfavorable decision, ruling or finding, would have a Material Adverse Effect.

     3.19 Good Title to Property. Sangamo and each Subsidiary has good and valid title to all
property (whether real or personal) described in Registration Statement and the Prospectus as being
owned by each of them, in each case free and clear of all liens, claims, security interests, other
encumbrances or defects (collectively, “Liens”), except such as are described in the Registration
Statement and the Prospectus and those that would not, individually or in the aggregate materially
affect the value of such property and do not materially interfere with the use made and proposed to
be made of such property by Sangamo and the Subsidiaries. All of the property described in the
Registration Statement and the Prospectus as being held under lease by Sangamo or any Subsidiary is
held thereby under valid, subsisting and enforceable leases, without any liens, restrictions,
encumbrances or claims, except those that, individually or in the aggregate, would not have a
Material Adverse Effect and do not materially interfere with the use made and proposed to be made
of such property by Sangamo and the Subsidiaries.

     3.20 Intellectual Property Rights. Except as set forth in the Registration Statement, and the
Prospectus, Sangamo and the Subsidiaries own or possess the right to use all patents, trademarks,
trademark registrations, service marks, service mark registrations, trade names, copyrights,
licenses, inventions, software, databases, know-how, Internet domain names, trade secrets and other
unpatented and/or unpatentable proprietary or confidential information, systems or procedures, and
other intellectual property (collectively, “Intellectual Property”) necessary to carry on their
respective businesses as currently conducted, and as proposed to be conducted and described in the
Prospectus, and Sangamo is not aware of any claim to the contrary or any

 7.

 

challenge by any other person to the rights of the Company and the Subsidiaries with respect
to the foregoing except for those that could not have a Material Adverse Effect. The Intellectual
Property licenses described in the Prospectus are, to the knowledge of Sangamo, valid, binding
upon, and enforceable by or against the parties thereto in accordance to its terms. Sangamo and
each Subsidiary has complied in all material respects with, and is not in breach nor has received
any asserted or threatened claim of breach of, any Intellectual Property license described in the
Prospectus, and Sangamo has no knowledge of any breach or anticipated breach by any other person to
any such Intellectual Property license. Sangamo and each Subsidiary’s businesses as now conducted
and as proposed to be conducted as set forth in the Registration Statement and the Prospectus, to
the knowledge of Sangamo, do not and will not infringe or conflict with any patents, trademarks,
service marks, trade names, copyrights, trade secrets, licenses or other Intellectual Property or
franchise right of any person. Sangamo has not received written notice of any material claim
against Sangamo or any Subsidiary alleging the infringement by the Sangamo or any Subsidiary of any
patent, trademark, service mark, trade name, copyright, trade secret, license in or other
intellectual property right or franchise right of any person. Sangamo and each Subsidiary has taken
all reasonable steps to protect, maintain and safeguard its rights in all Intellectual Property,
including the execution of appropriate nondisclosure and confidentiality agreements. The
consummation of the transactions contemplated by this Agreement will not result in the loss or
impairment of or payment of any additional amounts with respect to, nor require the consent of any
other person in respect of, Sangamo or any of Subsidiary’s right to own, use, or hold for use any
of the Intellectual Property as owned, used or held for use in the conduct of the businesses as
currently conducted. Sangamo and each Subsidiary has duly and properly filed or caused to be filed
with the United States Patent and Trademark Office (the “PTO”) and applicable foreign and
international patent authorities all patent applications owned by the Company and the Subsidiaries
(the “Company Patent Applications”). To the knowledge of Sangamo, Sangamo and each Subsidiary has
complied with the PTO’s duty of candor and disclosure for the Company Patent Applications and has
made no material misrepresentation in the Company Patent Applications. Sangamo is not aware of any
information material to a determination of patentability regarding the Company Patent Applications
not called to the attention of the PTO or similar foreign authority. Sangamo is not aware of any
information not called to the attention of the PTO or similar foreign authority that would preclude
the grant of a patent for the Company Patent Applications. Sangamo has no knowledge of any
information that would preclude the Company, or as applicable, any Subsidiary, from having clear
title to the Company Patent Applications.

     3.21 No Labor Disputes. No labor dispute with the employees of Sangamo exists, or, to
Sangamo’s knowledge, is threatened or imminent, which would reasonably be expected to result in a
Material Adverse Effect. Sangamo is not aware that any key employee or significant group of
employees of Sangamo plans to terminate employment with Sangamo.

     3.22 Taxes. Sangamo and each Subsidiary has (i) timely filed all necessary federal, state,
local and foreign income and franchise tax returns (or timely filed applicable extensions
therefore) that have been required to be filed and (ii) are not in default in the payment of any
taxes which were payable pursuant to said returns or any assessments with respect thereto, other
than any which Sangamo or any Subsidiary is contesting in good faith and for which adequate
reserves have been provided.

 8.

 

     3.23 Compliance with Environmental Laws. Sangamo and its Subsidiaries (a) are in compliance
with any and all applicable foreign, federal, state and local laws, orders, rules, regulations,
directives, decrees and judgments relating to the use, treatment, storage and disposal of hazardous
or toxic substances or waste and protection of human health and safety or the environment which are
applicable to their businesses (“Environmental Laws”), (b) have received and are in compliance with
all permits, licenses or other approvals required of them under applicable Environmental Laws to
conduct its business; and (c) have not received notice of any actual or potential liability for the
investigation or remediation of any disposal or release of hazardous or toxic substances or wastes,
pollutants or contaminants, except in the case of subsections (a), (b) and (c) of this subsection
as would not, individually or in the aggregate, have a Material Adverse Effect.

     3.24 Insurance. Sangamo and each Subsidiary maintains or is covered by insurance provided by
recognized, financially sound and reputable institutions with policies in such amounts and covering
such risks as is adequate for the conduct of its business and the value of its properties and as is
customary for companies engaged in similar businesses in similar industries. All such insurance is
fully in force on the date hereof and will be fully in force as of the Closing Date. Neither
Sangamo nor any Subsidiary has any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business at a cost that would not have a Material
Adverse Effect.

     3.25 Accounting Controls. Sangamo and each Subsidiary maintains (x) a system of internal
accounting controls sufficient to provide reasonable assurances that (i) transactions are executed
in accordance with management’s general or specific authorization; (ii) transactions are recorded
as necessary to permit preparation of financial statements in conformity with generally accepted
accounting principles and to maintain accountability for assets; (iii) access to assets is
permitted only in accordance with management’s general or specific authorization; and (iv) the
recorded accountability for assets is compared with existing assets at reasonable intervals and
appropriate action is taken with respect to any differences.

     3.26 Disclosure Controls. Sangamo has established, maintains and evaluates “disclosure
controls and procedures” (as such term is defined in Rule 13a-15e and 15d-15e under the Exchange
Act), which (i) are designed to ensure that material information relating to Sangamo is made known
to Sangamo’s principal executive officer and its principal financial officer by others within those
entities, particularly during the periods in which the periodic reports required under the Exchange
Act are being prepared, (ii) have been evaluated for effectiveness as of the end of the last fiscal
period covered by the Registration Statement; and (iii) such disclosure controls and procedures are
effective to perform the functions for which they were established. There are no significant
deficiencies and material weaknesses in the design or operation of internal controls which could
adversely affect Sangamo’s ability to record, process, summarize, and report financial data to
management and the Board of Directors.

     3.27 Contracts; Off-Balance Sheet Interests. There is no document, contract, permit or
instrument, or off-balance sheet transaction (including without limitation, any “variable
interests” in “variable interest entities,” as such terms are defined in Financial Accounting
Standards Board Interpretation No. 46) of a character required by the Securities Act or the Rules

 9.

 

and Regulations to be described in the Registration Statement or the Prospectus or to be filed
as an exhibit to the Registration Statement or document incorporated by reference therein, which is
not described or filed as required. The contracts described in the immediately preceding sentence
to which Sangamo is a party have been duly authorized, executed and delivered by Sangamo,
constitute valid and binding agreements of Sangamo, are enforceable against and by Sangamo in
accordance with the terms thereof and are in full force and effect on the date hereof.

     3.28 No Undisclosed Relationships. No relationship, direct or indirect, exists between or
among Sangamo and any of its Subsidiaries on the one hand and the directors, officers,
stockholders, customers or suppliers of Sangamo or any of its Subsidiaries or any of their
affiliates on the other hand, which is required to be described in the Registration Statement and
the Prospectus or a document incorporated by reference therein and which has not been so described.

     3.29 Forward-Looking Statements. No forward-looking statements (within the meaning of Section
27A of the Securities Act and Section 21E of the Exchange Act) contained in either the Registration
Statement or the Prospectus has been made or reaffirmed without a reasonable basis or has been
disclosed other than in good faith.

     3.30 Nasdaq; Exchange Act Registration. The Common Stock is registered pursuant to Section
12(b) or 12(g) of the Exchange Act and is listed on the Nasdaq Global Market, and Sangamo has taken
no action designed to, or reasonably likely to have the effect of, termination the registration of
the Common Stock under the Exchange Act or delisting the Common Stock from the Nasdaq Global
Market, nor has Sangamo received any notification that the Commission or the Nasdaq Global Market
is contemplating terminating such registration or listing.

     3.31 Sarbanes-Oxley Act. Sangamo, and to its knowledge, all of Sangamo’s directors or
officers, in their capacities as such, is in compliance in all material respects with all
applicable effective provisions of the Sarbanes-Oxley Act of 2002, as amended and any related rules
and regulations promulgated by the Commission. Each of the principal executive officer and the
principal financial officer of Sangamo (or each former principal executive officer of Sangamo and
each former principal financial officer of Sangamo as applicable) has made all certifications
required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules,
forms, statements and other documents required to be filed by it with the Commission. For purposes
of the preceding sentence, “principal executive officer” and “principal financial officer” shall
have the meanings given to such terms in the Sarbanes-Oxley Act.

     3.32 Foreign Corrupt Practices. Neither Sangamo nor, to Sangamo’s knowledge, any other person
associated with or acting on behalf of Sangamo, including without limitation any director, officer,
agent or employee of Sangamo or its Subsidiaries has, directly or indirectly, while acting on
behalf of Sangamo or its Subsidiaries (i) used any corporate funds for unlawful contributions,
gifts, entertainment or other unlawful expenses relating to political activity or failed to
disclose fully any contribution in violation of law, (ii) made any payment to any federal or state
governmental officer or official, or other person charged with similar public or quasi-public
duties, other than payments required or permitted by the laws of the United States or any

 10.

 

jurisdiction thereof, (iii) violated or is in violation of any provision of the U.S. Foreign
Corrupt Practices Act of 1977, as amended or (iv) made any bribe, rebate, payoff, influence
payment, kickback or other unlawful payment.

     3.33 Statistical or Market-Related Data. Any statistical, industry-related and market-related
data included or incorporated by reference in the Registration Statement or the Prospectus are
based on or derived from sources that Sangamo reasonably and in good faith believes to be reliable
and accurate, and such data agree with the sources from which they are derived.

     3.34 Clinical Studies. The clinical, pre-clinical and other studies and tests conducted by or
on behalf of or sponsored by Sangamo or in which Sangamo or the Subsidiaries or products or product
candidates have participated that are described in the Registration Statement and the Prospectus
were and, if still pending, are being conducted in accordance in all material respects with all
applicable federal, state or foreign statutes, laws, rules and regulations (including, without
limitation, those administered by the FDA or by any foreign, federal, state or local governmental
or regulatory authority performing functions similar to those performed by the FDA and current Good
Laboratory and Good Clinical Practices) and in accordance with experimental protocols, procedures
and controls pursuant to, where applicable, accepted professional scientific methods. The
descriptions in the Registration Statement and the Prospectus of the results of such studies, tests
and trials are accurate and complete in all material respects and fairly present the published data
derived from such studies, tests and trials. Neither Sangamo nor any Subsidiary have received any
notices or other correspondence from the FDA or any other foreign, federal, state or local
governmental or regulatory authority performing functions similar to those performed by the FDA
with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination,
suspension or material modification of such studies, tests or preclinical or clinical trials, which
termination, suspension or material modification would reasonably be expected to result in a
Material Adverse Effect.

     3.35 Continued Compliance with Securities Law. If, during the period in which Sangamo is
required to deliver the Prospectus in connection with the issuance and sale of the Shares
(“Prospectus Delivery Period”), any event occurs as a result of which the Prospectus as then
amended or supplemented would include an untrue statement of a material fact or omit to state any
material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading, or if it is necessary at any time to amend the Registration
Statement or supplement the Prospectus to comply with the Securities Act, the Company will promptly
notify Sigma of such event and will promptly prepare and file with the Commission and furnish, at
its own expense, to Sigma, a copy of such amendment or supplement which will correct such statement
or omission or an amendment which will effect such compliance.

     3.36 SEC Filings. Sangamo will file all reports and any definitive proxy or information
statements required to be filed by the Company with the Commission pursuant to Section 13(a),
13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and during the
Prospectus Delivery Period.

 11.

 

ARTICLE 4

Representations, Warranties and Covenants of Sigma

     Sigma represents and warrants to, and covenants and agrees with, Sangamo, as of the date
hereof and as of the date of Closing, as follows:

     4.1 Due Organization. Sigma is a corporation duly organized under the laws of the State of
Delaware, and has all necessary power and authority to conduct its business in the manner in which
it is currently being conducted. Sigma is duly qualified to do business and is in good standing as
a foreign corporation in each jurisdiction where the ownership or operation of its assets or the
conduct of its business requires such qualification, except for failures to be so qualified or in
good standing, as the case may be, that would not individually or in the aggregate have a material
adverse effect on Sigma.

     4.2 Authority; Binding Nature of Agreement. Sigma has the right, power and authority to enter
into and perform its obligations under this Agreement. The execution, delivery and performance of
this Agreement by Sigma have been duly authorized by all necessary corporate action on the part of
Sigma. Assuming due execution by Sangamo, this Agreement constitutes the legal, valid and binding
obligation of Sigma, enforceable against Sigma in accordance with its terms, subject to (a) laws of
general application relating to bankruptcy, insolvency and the relief of debtors, and (b) rules of
law governing specific performance, injunctive relief and other equitable remedies.

     4.3 Non-Contravention. The execution, delivery and performance of this Agreement by Sigma,
and the consummation by Sigma of the transactions contemplated hereby, do not (i) contravene or
conflict with the organizational documents Sigma; (ii) constitute a violation of any provision of
any federal, state, local or foreign law, rule, regulation, order or decree applicable to Sigma; or
(iii) constitute a default or require any consent under, give rise to any right of termination,
cancellation or acceleration of, or to a loss of any material benefit to which Sigma is entitled
under, or result in the creation or imposition of any lien, claim or encumbrance on any asset of
Sigma under, any material contract to which Sigma is a party or any material permit, license or
similar right relating to Sigma or by which Sigma may be bound or affected.

     4.4 Short Sale. Neither Sigma nor any person acting on behalf of, or pursuant to any
understanding with or based upon any information received from, Sigma has, directly or indirectly,
engaged in any transactions in the securities of Sangamo (including, without limitation, any Short
Sales involving Sangamo’s securities). “Short Sales” include, without limitation, all “short
sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or
not against the box, and all types of direct and indirect stock pledges, forward sale contracts,
options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h)
under the Exchange Act) and similar arrangements (including on a total return basis), and sales and
other transactions through non-U.S. broker dealers or foreign regulated brokers.

     4.5 Lock-Up Period. Beginning on the date hereof and continuing for a period of 180 days,
Sigma and its affiliate shall not (i) sell, offer to sell offer, hypothecate, pledge,

 12.

 

announce the intention to sell, contract to sell, sell any option or contract to purchase,
grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or
indirectly, with respect to any Shares or (ii) enter into any swap, hedge or other agreement that
transfers, in whole or in part, any of the economic consequences of ownership of the Shares,
without the prior written consent of Sangamo (which consent may be withheld in Sangamo’s sole
discretion). Sigma acknowledges that the certificate representing the Shares being purchased
hereunder shall contain an appropriate legend regarding the foregoing transfer restriction.

ARTICLE 5

MISCELLANEOUS

     5.1 Governing Law. Resolution of all disputes arising out of or related to this Agreement or
the performance, enforcement, breach or termination of this Agreement and any remedies relating
thereto, shall be governed by and construed under the substantive laws of the State of Delaware,
without regard to conflicts of law rules that would cause the application of the laws of another
jurisdiction.

     5.2 Entire Agreement; Amendment. This Agreement set forth the complete, final and exclusive
agreement and all the covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties hereto and supersedes and terminates all prior agreements and
understandings between the Parties with respect to the matters contemplated hereby. No subsequent
alteration, amendment, change or addition to this Agreement shall be binding upon the Parties
unless reduced to writing and signed by an authorized officer of each Party.

     5.3 Notices. Any notice required or permitted to be given under this Agreement shall be in
writing, shall specifically refer to this Agreement and shall be deemed to have been sufficiently
given for all purposes if mailed by first class certified or registered mail, postage prepaid,
express delivery service or personally delivered. Unless otherwise specified in writing, the
mailing addresses of the Parties shall be as described below.

	 	 	 	 	 
	 

	 	For Sangamo:
	 	Sangamo BioSciences, Inc.
	 

	 	 	 	Point Richmond Tech Center
	 

	 	 	 	501 Canal Boulevard, Suite A100
	 

	 	 	 	Richmond, California 94804
	 

	 	 	 	Attention: Chief Executive Officer
	 
	 	 	 	 
	 

	 	For Sigma:
	 	Sigma Aldrich Corp.
	 

	 	 	 	3050 Spruce Street
	 

	 	 	 	St. Louis, Mo 63103
	 

	 	 	 	Attention: General Counsel

     5.4 No Strict Construction. This Agreement has been prepared jointly and shall not be
strictly construed against either Party. Ambiguities, if any, in this Agreement shall not be

 13.

 

construed against any Party, irrespective of which Party may be deemed to have authored the
ambiguous provision.

     5.5 Successors and Assigns. This Agreement shall inure to the benefit of the successors and
assigns of Sangamo and, subject to any restrictions on the transfer of the Shares, be binding upon
Sigma’s successors and assigns.

     5.6 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     5.7 Further Actions. Each Party agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate in order to carry
out the purposes and intent of this Agreement.

     5.8 Severability. If any one or more of the provisions of this Agreement is held to be
invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is
taken, the provision shall be considered severed from this Agreement and shall not serve to
invalidate any remaining provisions hereof. The Parties shall make a good faith effort to replace
any invalid or unenforceable provision with a valid and enforceable one such that the objectives
contemplated by the Parties when entering this Agreement may be realized.

     5.9 Headings. The headings for each article and section in this Agreement have been inserted
for convenience of reference only and are not intended to limit or expand on the meaning of the
language contained in the particular article or section.

     5.10 No Waiver. Any delay in enforcing a Party’s rights under this Agreement or any waiver as
to a particular default or other matter shall not constitute a waiver of such Party’s rights to the
future enforcement of its rights under this Agreement, excepting only as to an express written and
signed waiver as to a particular matter for a particular period of time.

[Rest of Page Intentionally Left Blank]

 14.

 

     In Witness Whereof, the Parties have executed this Common Stock Purchase Agreement in
duplicate originals by their proper officers as of the date and year first above written.

	 	 	 	 	 	 	 	 	 
	Sangamo BioSciences, Inc.	 	 	 	Sigma-Aldrich Corporation
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Edward Lanphier	 	 	 	By:	 	/s/ Michael R. Hogan
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Name:

	 	Edward Lanphier
	 	 	 	Name:	 	 Michael R. Hogan
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Title:

	 	President and CEO, Sangamo BioSciences, Inc.
	 	 	 	Title:	 	Chief Financial Officer
	 

	 	 
	 	 	 	 	 	 

 15.

 

Schedule 1.7

Edward Lanphier

Greg Zante

David Ichikawa

 

 

Schedule 3.7

Gendaq Limited

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]